Posts

Showing posts from November, 2026

USA-based CMO insulin manufacturing partner and biomanufacturer built to capture global insulin market share.

Image
  MayMag Biologics: Domestic Biomanufacturing Supply Chain & Federal Biologic CDMO Partner MayMag Biologics is a Dallas, Texas-based, USA-based cGMP contract development and manufacturing organization (CDMO) and FDA-registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA). Operating dual cGMP-certified facilities in Dallas and Garland, Texas, MayMag provides pharmaceutical sponsors, research institutions, compounding pharmacies, and specialty distributors nationwide with a fully domestic U.S. supply chain—eliminating dependence on overseas API manufacturers. Federal & Defense Contracting Credentials Registrations & Compliance: Leading federal biologic CDMO partner, SAM.gov subcontractor, GSA/SAM registered biologic manufacturer, and FAR-compliant contract manufacturing pharma provider. Codes & Standards: Certified for NAICS 325414 Biological Products, NAICS 325412 Pharmaceutical Preparations, 6505 Biologicals and Formal Compounds, and...

Sterile Fill-Finish & 506(e) Outsourcing Facility For Epi Pen, GLP1 and Diabetes Biologics

Image
  Accelerate Delivery and Scale with MayMag Biologics —the premier biologics drug delivery device contract manufacturer, insulin pen OEM supplier, and elite biopharmaceutical parenteral delivery device supplier. Headquartered in Dallas, Texas, with dual cGMP-certified facilities in Dallas and Garland, MayMag Biologics is a USA-based CMO insulin manufacturing partner and cGMP contract development and manufacturing organization (CDMO) built to help sponsors capture global insulin market share and lower global healthcare costs. We bridge the gap between complex drug substance synthesis and commercial-scale device assembly. As your recombinant insulin API supplier and autoinjector CDMO manufacturing partner, we specialize in large-scale biologics manufacturing and large-scale recombinant protein production targeting FDA approval for interchangeable biosimilar insulin. Our expanded CDMO sterile fill-finish services support biosimilar insulins—including Icodec, Degludec, Glargine, Detemi...

MayMag Biologics provides a fully domestic biomanufacturing supply chain with Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing

Image
  MayMag Biologics is a leading federal biologic CDMO partner, SAM.gov subcontractor, and GSA/SAM registered biologic manufacturer delivering FAR-compliant contract manufacturing for pharma across NAICS 325414 (Biological Products) , NAICS 325412 (Pharmaceutical Preparations) , PSC 6505 (Biologicals and Formal Compounds) , and AI14 (Defense R&D; medical pharmaceuticals) . Operating out of dual cGMP-certified facilities in the Dallas–Fort Worth metroplex (Dallas and Garland, Texas), MayMag Biologics provides a fully domestic biomanufacturing supply chain with Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing—eliminating dependence on overseas API manufacturers. As a USA-based cGMP contract development and manufacturing organization (CDMO) and FDA-registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA), MayMag operates under direct FDA oversight—distinct from traditional state-regulated compounding pharmacies. We serve p...

MayMag Biologics- USA-based CMO Insulin Autopen Manufacturing Partner

Image
 MayMag Biologics-Leading federal Biologic CDMO Partner for SAM.gov Subcontractor, Biomanufacturer, federal pharmaceutical CDMO partner, GSA/SAM registered biologic manufacturer, FAR-compliant contract manufacturing Pharma for NAICS 325414 Biological Products, NAICS 325412 Pharmaceutical Preparations, 6505 Biologicals, and Formal Compounds, AI14 Defense R&D; medical pharmaceuticals; domestic biomanufacturing supply chain, Berry Amendment-compliant pharmaceuticals, TAA-compliant drug manufacturing, USA-based cGMP contract development and manufacturing organization (CDMO) offering Sterile injectable fill-finish services.   MayMag Biologics is the No. 5 Leading Insulin Self-Injection Device OEM & 3 mL cartridge insulin delivery pen manufacturer with 506 (e) registration with the USFDA. Premier GLP-1 Peptide Pen Injector Contract Manufacturing. A Leading Biologics CDMO For Insulin API And Large-Scale Recombinant Protein Production to Capture Global Insulin Market Share...

MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

Image
  MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors FDA-registered Section 506(e) outsourcing facility and U.S. CDMO offers audit-ready sterile injectable biologics and Rx/OTC oral solid dosage manufacturing to strengthen domestic federal medical supply chains. MayMag Biologics Corp (formerly Tirzepatide Pharma), an FDA-registered Section 506(e) outsourcing facility and U. S. -based Contract Development and Manufacturing Organization (CDMO), announced today the expansion of its domestic co-manufacturing and fill-finish partnerships tailored specifically for SAM. gov prime contract awardees. Operating dual cGMP-certified manufacturing facilities in Dallas and Garland, Texas, MayMag Biologics provides federal prime contractors with a compliant, onshore partner for sterile injectable biologics and prescription (Rx) and over-the-counter (OTC) oral solid dosages. As federal agencies—including the Department...

Insulin Biosimilar Autoinjector CDMO Manufacturing, Prefilled Syringe, Insulin Pen OEM Supplier, Biologics Drug Delivery Device Contract Manufacturer, Sterile Fill-Finish Prefilled Syringes Biologics,

Image
 MayMag Biologics is the No. 5 Leading Insulin Self-Injection Device OEM & 3 mL cartridge insulin delivery pen manufacturer with 506 (e) registration with the USFDA. Premier GLP-1 Peptide Pen Injector Contract Manufacturing. A Leading Biologics CDMO For Insulin API And Large-Scale Recombinant Protein Production to Capture Global Insulin Market Share. MayMag Biologics Is Your Recombinant Insulin API Supplier and Autoinjector CDMO Manufacturing Partner For Large-Scale Biologics Manufacturing Targeting FDA Approval For Interchangeable Biosimilar Insulin. MayMag Biologics Provides 21 CFR 4 Combination Product Contract Manufacturing, GLP-1 Pen Injector Supplier Services, And Annex 1-Compliant Sterile Fill-Finish Syringes.  Premier Biologics Drug Delivery Device Contract Manufacturer and Insulin Pen OEM Supplier. Experts In Sterile Fill-Finish, Prefilled Syringes, Biologics, Epinephrine, And Autoinjectors.  Accelerate Delivery with MayMag Biologics—Your Custom Pen Injecto...

MayMag Biologics Expands Global Reach with Advanced Biologics CMO Capabilities and Strategic Biosimilar Insulin Supply Chain Partnerships

  Dallas, Texas — MayMag Biologics , an FDA-registered 506(e) outsourcing facility and contract development and manufacturing organization (CDMO), today announced the expansion of its commercial sterile fill-finish and Large-Scale Recombinant Protein Production capabilities. Positioned as a premier Biologics CMO Insulin Manufacturing partner, MayMag Biologics is strengthening the global biopharmaceutical supply chain by partnering with tier-one API Insulin Suppliers and global biosimilar leaders to address critical drug shortages and enhance global access to essential metabolic therapies. As a leading Recombinant Insulin API Supplier partner and CDMO, MayMag Biologics provides end-to-end aseptic fill-finish, lyophilization, auto-pen assembly (including U-100, U-200, and U-700 concentrations), and cold-chain packaging for next-generation insulin analogs, such as Insulin Icodec, Degludec, Glargine, Detemir, and Aspart. Securing a Strategic Position in the Biosimilar Landscape W...

Navigating the Future of Biopharmaceutical Delivery: Scaling Interchangeable Biosimilar Insulin and Advanced Injectable Devices

  The biopharmaceutical landscape is undergoing a monumental shift. As loss-of-exclusivity milestones open pathways for biosimilars and chronic disease populations expand globally, biopharma developers face dual imperatives: ensuring strict regulatory compliance under FDA guidelines and scaling sterile drug-device manufacturing without compromising quality or yield. At MayMag Biologics , we bridge the gap between complex drug formulation, regulatory alignment, and commercial-scale execution. As a specialized Biologics Drug Delivery Device Contract Manufacturer and Autoinjector CDMO Manufacturing partner, MayMag Biologics provides integrated end-to-end solutions designed to bring high-potency biopharmaceuticals, biosimilars, and combo products to global markets seamlessly. 1. Navigating FDA Approval for Interchangeable Biosimilar Insulin Achieving Interchangeable Biosimilar Insulin FDA Approval demands rigorous analytical characterization, extensive comparative clinica...